Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Kefu Medical (301087), indicating a slight decline in stock price and mixed capital flow on December 26, 2025 [1][2] - As of December 26, 2025, Kefu Medical's stock closed at 44.97 yuan, down 1.47%, with a turnover rate of 0.67% and a trading volume of 13,000 hands, resulting in a transaction amount of 58.5951 million yuan [1] - The capital flow data on December 26 shows a net outflow of 479.68 thousand yuan from main funds, accounting for 8.19% of the total transaction amount, while retail investors saw a net inflow of 170.81 thousand yuan, representing 2.92% of the total [1] Group 2 - Kefu Medical's Q3 2025 report reveals a total revenue of 2.398 billion yuan for the first three quarters, reflecting a year-on-year increase of 6.63%, and a net profit attributable to shareholders of 260 million yuan, up 3.3% [2] - In Q3 2025 alone, the company achieved a revenue of 902 million yuan, marking a significant year-on-year increase of 30.72%, and a net profit of approximately 92.83 million yuan, which is up 38.68% [2] - The company maintains a debt ratio of 27.37%, with an investment income of 18.18 million yuan and a financial expense of -3.77 million yuan, alongside a gross profit margin of 53.35% [2]
股票行情快报：可孚医疗（301087）12月26日主力资金净卖出479.68万元